IL240805B - Naphthyridine and quinoline compounds as mao inhibitors - Google Patents

Naphthyridine and quinoline compounds as mao inhibitors

Info

Publication number
IL240805B
IL240805B IL240805A IL24080515A IL240805B IL 240805 B IL240805 B IL 240805B IL 240805 A IL240805 A IL 240805A IL 24080515 A IL24080515 A IL 24080515A IL 240805 B IL240805 B IL 240805B
Authority
IL
Israel
Prior art keywords
quinoline compounds
mao inhibitors
substituted naphthyridine
naphthyridine
substituted
Prior art date
Application number
IL240805A
Other languages
English (en)
Hebrew (he)
Other versions
IL240805A0 (en
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of IL240805A0 publication Critical patent/IL240805A0/en
Publication of IL240805B publication Critical patent/IL240805B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL240805A 2013-03-14 2015-08-25 Naphthyridine and quinoline compounds as mao inhibitors IL240805B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785872P 2013-03-14 2013-03-14
PCT/US2014/020881 WO2014158916A1 (en) 2013-03-14 2014-03-05 Substituted naphthyridine and quinoline compounds as mao inhibitors

Publications (2)

Publication Number Publication Date
IL240805A0 IL240805A0 (en) 2015-10-29
IL240805B true IL240805B (en) 2018-07-31

Family

ID=51530146

Family Applications (1)

Application Number Title Priority Date Filing Date
IL240805A IL240805B (en) 2013-03-14 2015-08-25 Naphthyridine and quinoline compounds as mao inhibitors

Country Status (15)

Country Link
US (4) US9150572B2 (enExample)
EP (1) EP2970125B1 (enExample)
JP (1) JP6346658B2 (enExample)
KR (1) KR20150127172A (enExample)
CN (1) CN105143190B (enExample)
AU (1) AU2014241759B2 (enExample)
BR (1) BR112015022202A2 (enExample)
CA (1) CA2895287A1 (enExample)
IL (1) IL240805B (enExample)
MX (1) MX2015011144A (enExample)
NZ (1) NZ711598A (enExample)
RU (1) RU2661156C2 (enExample)
SG (1) SG11201504704TA (enExample)
TW (1) TWI657078B (enExample)
WO (1) WO2014158916A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015022202A2 (pt) 2013-03-14 2017-07-18 Dart Neuroscience Cayman Ltd compostos substituídos de naftiridina e quinolina como inibidores da mao
CA2960386A1 (en) * 2014-09-17 2016-03-24 Dart Neuroscience (Cayman) Ltd. Mao-b inhibitors and rehabilitation
CN104496998B (zh) * 2014-12-15 2017-07-11 陕西嘉禾生物科技股份有限公司 一种1′‑苄基‑2′‑酮‑5′，7′，8′‑三氢‑螺‑[1，3‑二氧五环‑2]‑喹啉的制备方法
WO2016125187A1 (en) 2015-02-03 2016-08-11 Council Of Scientific & Industrial Research Novel quinoline derivatives and preparation thereof
WO2016179434A1 (en) 2015-05-05 2016-11-10 Dart Neuroscience, Llc Systems and methods for cognitive testing
US11603431B2 (en) 2016-02-04 2023-03-14 Raynergy Tek Incorporation Organic semiconductors
CN110234635B (zh) * 2016-09-14 2023-03-10 宇凤·简·曾 作为d-胺基酸氧化酶(daao)抑制剂之新颖经取代苯并咪唑衍生物
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California Compounds for increasing neural plasticity
CN107216331B (zh) * 2017-07-07 2019-06-18 华南理工大学 一种四氢萘啶并四氢喹唑啉衍生物及其合成方法和应用
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CN108658977A (zh) * 2018-04-12 2018-10-16 苏州康润医药有限公司 一种7-溴-1,5-萘啶-3-甲酸的合成方法
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
EP3930708A4 (en) 2019-02-27 2023-02-15 The Regents Of The University Of California N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR THE TREATMENT OF BRAIN DISORDERS
CN112939952A (zh) * 2021-02-02 2021-06-11 深圳市第二人民医院(深圳市转化医学研究院) 一种3-羟基查尔酮衍生物及其用途
CN112898276A (zh) * 2021-02-02 2021-06-04 深圳市第二人民医院(深圳市转化医学研究院) 一种查尔酮衍生物及其用途
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
CN114437068A (zh) * 2022-02-21 2022-05-06 深圳市儿童医院 一种萘啶衍生物及其作为单胺氧化酶抑制剂的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138540A (en) * 1966-09-19 1969-01-01 Ici Ltd Quinoline derivatives
SU550385A1 (ru) * 1975-09-22 1977-03-15 Институт Биологической И Медицинской Химии Амн Ссср 8-( -Метил - -пропинил-2)-аминометилхинолин как ингибитор моноаминоксидазы и способ его получени
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH04295470A (ja) 1991-03-22 1992-10-20 Wakamoto Pharmaceut Co Ltd モノアミンオキシダーゼ−ｂ酵素阻害活性を有する１，２，４−オキサジアゾール誘導体及びその製造法
US5510361A (en) 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
WO1998020871A1 (en) 1996-11-08 1998-05-22 Nippon Chemiphar Co., Ltd. Visceral fat lowering agent
EP0994095A1 (en) 1996-12-24 2000-04-19 Nippon Chemiphar Co., Ltd. Propionic acid derivatives
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
AU2001284792A1 (en) 2000-08-10 2002-02-25 Cold Spring Harbor Laboratory Augmented cognitive training
JP2002322163A (ja) * 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd ピペラジン誘導体
FR2834640B1 (fr) 2002-01-11 2004-09-24 Lipha Composition pharmaceutique comprenant une glitazone et un acide 4-oxobutanoique et son utilisation pour traiter le diabete
KR101010905B1 (ko) 2002-01-18 2011-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아실아미노티아졸 유도체 또는 그 염
US6761089B2 (en) 2002-07-01 2004-07-13 Proqual, Llc Tool for removing screws with damaged heads
MY134480A (en) 2002-09-20 2007-12-31 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
WO2005003951A1 (ja) 2003-07-02 2005-01-13 Satoshi Yamatake データベースシステム
RU2006117366A (ru) * 2003-10-23 2007-12-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные бензазепина в качестве ингибиторов мао-в
US7501528B2 (en) 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
RU2392276C2 (ru) 2005-03-29 2010-06-20 Ньюрон Фармасьютикалс С.П.А. Замещенные аминоалкил- и амидоалкилбензопиранпроизводные
US8138209B2 (en) 2005-07-13 2012-03-20 Jenrin Discovery, Inc. Substituted picolinamides as MAO-B inhibitors useful for treating obesity
JP5503874B2 (ja) 2006-02-28 2014-05-28 ダート ニューロサイエンス （ケイマン） エルティーディー 治療化合物
BRPI0811623A2 (pt) 2007-05-15 2014-11-11 Helicon Therapeutics Inc Métodos para identificar genes envolvidos na formação de memória usando pequeno rna interferente (sirna)
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
KR20110036583A (ko) * 2008-06-20 2011-04-07 로타팜 에스.피.에이. 6-1ｈ-이미다조-퀴나졸린 및 퀴놀린 유도체, 신규 ｍａｏ 억제제 및 이미다졸린 수용체 리간드
CA2741668A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
ES2343347B2 (es) 2009-01-27 2011-12-07 Universidade De Santiago De Compostela Uso de derivados de 3-fenilcumarinas 6-sustituidas y preparacion de nuevos derivados.
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
BR112015022202A2 (pt) 2013-03-14 2017-07-18 Dart Neuroscience Cayman Ltd compostos substituídos de naftiridina e quinolina como inibidores da mao

Also Published As

Publication number Publication date
KR20150127172A (ko) 2015-11-16
EP2970125B1 (en) 2018-07-18
JP2016512256A (ja) 2016-04-25
RU2015137619A (ru) 2017-04-20
SG11201504704TA (en) 2015-07-30
JP6346658B2 (ja) 2018-06-20
AU2014241759B2 (en) 2017-10-19
CA2895287A1 (en) 2014-10-02
WO2014158916A1 (en) 2014-10-02
US9150572B2 (en) 2015-10-06
TWI657078B (zh) 2019-04-21
US9675605B2 (en) 2017-06-13
US9102674B2 (en) 2015-08-11
CN105143190A (zh) 2015-12-09
MX2015011144A (es) 2016-02-09
RU2661156C2 (ru) 2018-07-12
IL240805A0 (en) 2015-10-29
US9956213B2 (en) 2018-05-01
AU2014241759A1 (en) 2015-09-17
EP2970125A1 (en) 2016-01-20
US20170312263A1 (en) 2017-11-02
CN105143190B (zh) 2017-08-18
US20140275548A1 (en) 2014-09-18
NZ711598A (en) 2016-09-30
TW201506012A (zh) 2015-02-16
EP2970125A4 (en) 2016-07-27
US20140315944A1 (en) 2014-10-23
BR112015022202A2 (pt) 2017-07-18
US20160074377A1 (en) 2016-03-17
HK1220185A1 (en) 2017-04-28

Similar Documents

Publication Publication Date Title
IL279682A (en) Benzoquinolone compounds as VMAT2 inhibitors
IL240805B (en) Naphthyridine and quinoline compounds as mao inhibitors
ZA201600514B (en) Quinoline derivative
IL243479B (en) New quinazolinones as bromodomain inhibitors
EP2970340A4 (en) BETA-Lactamase INHIBITORS
EP2943204A4 (en) BETA-Lactamase INHIBITORS
IL241158B (en) Interference of heterocyclic tricyclics as protein inhibitors
PL2951177T3 (pl) Związki imidazopirydynowe i ich zastosowania
IL239827A0 (en) Deoxyuridine triphosphatase inhibitors
ZA201506156B (en) Novel inhibitors
GB201312318D0 (en) Novel methods and compounds
IL246230A0 (en) Amines thf quinazoline as pde1 inhibitors
ZA201508968B (en) Imidazo-triazine derivatives as pde10 inhibitors
EP2885291A4 (en) INHIBITORS OF VEGFR3
IL244617A0 (en) Benzoquinolone compounds as vmat2 inhibitors
EP2885292A4 (en) VEGFR3 INHIBITORS
IL240763A0 (en) The halopyrazoles as thrombin inhibitors
GB201309603D0 (en) Novel compounds and their use as kinase inhibitors
GB201305741D0 (en) Novel compounds and their use as kinase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed